Transform Your Employee Benefits to a Competitive Advantage

1. Zolgensma ($2,125,000) Spinal muscular atrophy (SMA), a rare disease that causes muscular erosion. Prevalence: 1 in 10,000 live births. Novartis allows annuity payments over a five-year period and delayed reimbursement to ensure the therapy works.

2. Carbaglu ($1,598,822) Hyperammonemia, a urea cycle disorder caused by lack of a certain liver enzyme, which elevates ammonia levels. Prevalence: 1 in 25,000 live births.

3. Procysbi ($1,085,160) Nephropathic cystinosis, a rare hereditary metabolic disorder that causes kidney problems, slow growth, weak bones, and eye problems. Prevalence: 1 in 200,000 live births.

4. Zokinvy ($1,032,480) Hutchinson-Gilford Progeria Syndrome, a rare disease that causes premature aging. Prevalence: 1 in 4 million live births. Most patients die before the age of 15 from heart failure or stroke.

5. Danyelza ($977,664) Neuroblastoma bone marrow cancer. Prevalence: 10 in 1 million children under 15. 6. Myalept ($889,904) Leptin deficiency, which causes an abnormal fat distribution in the body. Prevalence: 5 in 1 million people annually in the U.S. Aegerion Pharmaceuticals offers a copay card to assist commercially insured patients.

7. Luxturna ($850,000) A curative gene therapy, which treats an inherited retinal disease that causes blindness. Prevalence: 4 - 10 people in 1 million lives in the U.S.

8. Folotyn ($817,865) Peripheral t-cell lymphoma, a rare blood cancer. Prevalence: 1 in 100,000 people in the U.S. every year.

9. Amondys 45, Exondys 51, Vyondys 53 ($748,800) Duchenne Muscular Dystrophy, a rare disease caused by over 2,000 mutations of the dystrophin gene, causing progressive loss of skeletal and cardiac function and ultimately death. Prevalence: 1 in every 3,500 live male births.

10. Brineura ($730,340) Batten Disease, a rare pediatric brain disorder that causes seizures, loss of muscle coordination and vision loss. Prevalence: 20 children in the U.S. annually. BioMarin offers free genetic testing through Behind the Seizure. The McGriff National Pharmacy Practice can help employers explore unique solutions which allow greater control of pharmacy spend and ensure quality clinical outcomes. Contact Denise Cabrera or your McGriff representative for further information.

SOURCES: 1. “Projections of National Health Expenditures and Health Insurance Enrollment:

Methodology and Model Specification.” 24 March 2020, https://www.cms.gov/Research-Statistics-Data-and-Systems/

Statistics-Trends-and-Reports/NationalHealthExpendData/

Downloads/ProjectionsMethodology.pdf 2. Round 2 Of January 2022 Hikes Pushes Blockbuster Prices To New Heights | Patients For Affordable Drugs 3. https://rarediseases.org/ 4. https://professionals.optumrx.com/publications/rx-highlights.html 5. https://www.fda.gov/drugs/development-approval-process-drugs/ drug-approvals-and-databases

Denise Cabrera, Licensed Clinical Pharmacist

National Pharmacy Practice Leader McGriff Employee Benefit Solutions

Denise.Cabrera@mcgriffin.com

Transform your employee benefits from an expense to a competitive advantage...with McGriff MORE InsightsTM

Our proprietary approach helps you quantify and achieve optimal plan performance across four key areas of your employee benefits program – Managing Costs, Operational Efficiency, Risk Mitigation and the Employee Experience by answering three key questions: • How is your organization doing? • Where should you aim? • What’s the value in getting there? By optimizing benefit plan selection, design, management, and employee engagement, McGriff MORE InsightsTM can help turn your benefits program into a real differentiator that aligns with your organization’s culture and business objectives. Visit www.McGriff.com to learn more.

© 2022 McGriff Insurance Services, Inc. All rights reserved. McGriff Insurance Services, Inc. is a subsidiary of Truist Insurance Holdings.